GlassScriptPhysician profile
Jessica Murphy
NPI 1235591223
$5,454.03
in general payments reported to CMS, 2019-2025
27 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $99.00 · 2021: $82.38 · 2022: $619 · 2023: $821 · 2024: $1,638 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,188.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.63 | 2021-2025 | |
| Amgen INC. | $882.27 | 2022-2025 | Evenity, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $565.58 | 2024-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $311.47 | 2022-2025 | Saphnelo, Flumist Quadrivalent |
| Ucb, INC. | $234.21 | 2022-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $224.26 | 2019-2025 | Gazyva |
| Glaxosmithkline, LLC. | $212.87 | 2019-2025 | Benlysta, Nucala |
| Alexion Pharmaceuticals, INC. | $159.92 | 2023-2025 | Strensiq, Ultomiris |
| Lilly USA, LLC | $132.70 | 2022-2025 | Taltz, Zepbound |
| Merck Sharp & Dohme LLC | $120.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.83 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.40 | 2019-2025 | Orencia |
| Sobi, INC | $104.23 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $100.87 | 2023-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $97.72 | 2022-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.67 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $87.55 | 2023-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $58.81 | 2023-2025 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $42.11 | 2023-2024 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $41.19 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.63 | 2024-2025 | Ofev |
| Fresenius Kabi USA, LLC | $29.62 | 2023-2024 | Idacio |
| Genzyme Corporation | $26.84 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $17.52 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.67 | 2023 | |
| Scilex Pharmaceuticals INC. | $13.93 | 2025 | |
| Organon LLC | $11.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.